metabolism of cortsiol inckuding salibvary ,kidney and liver

I'll read the medical library skill first, then research cortisol metabolism comprehensively.
Reading File
Now let me search the medical library and web simultaneously for cortisol metabolism.
Finding Sources
Finding Sources
Searching the Web

cortisol metabolism liver kidney salivary gland 11beta-HSD biochemistry

Now let me pull the relevant textbook sections and search for images in parallel.
Reading File
Reading File
Finding Sources
Searching Images

cortisol metabolism 11beta-HSD liver kidney pathway diagram

This pathophysiology diagram illustrates the systemic effects of cortisol on glucose metabolism across various human tissues. At the center is the chemical steroid structure of cortisol, with arrows indicating its multi-organ impact. 1) Liver: Shows increased (+) gluconeogenesis and glycogen storage. 2) Smooth Muscle: Depicts decreased (-) glucose uptake/oxidation and glycogen storage, but increased (+) amino acid precursor availability for gluconeogenesis. 3) Pancreas: Illustrates inhibition (-) of insulin secretion from beta cells and glucagon secretion from alpha cells, alongside induced (+) beta cell hyperplasia. 4) White Adipose Tissue: Shows decreased (-) glucose uptake/oxidation and increased (+) lipolysis, which provides glycerol for hepatic gluconeogenesis. The visual summarizes the hormonal role of glucocorticoids in mobilizing energy substrates and maintaining blood glucose levels, often associated with the metabolic response to stress. This educational material is suitable for students of endocrinology and metabolic physiology.

This pathophysiology diagram illustrates the systemic effects of cortisol on glucose metabolism across various human tissues. At the center is the chemical steroid structure of cortisol, with arrows indicating its multi-organ impact. 1) Liver: Shows increased (+) gluconeogenesis and glycogen storage. 2) Smooth Muscle: Depicts decreased (-) glucose uptake/oxidation and glycogen storage, but increased (+) amino acid precursor availability for gluconeogenesis. 3) Pancreas: Illustrates inhibition (-) of insulin secretion from beta cells and glucagon secretion from alpha cells, alongside induced (+) beta cell hyperplasia. 4) White Adipose Tissue: Shows decreased (-) glucose uptake/oxidation and increased (+) lipolysis, which provides glycerol for hepatic gluconeogenesis. The visual summarizes the hormonal role of glucocorticoids in mobilizing energy substrates and maintaining blood glucose levels, often associated with the metabolic response to stress. This educational material is suitable for students of endocrinology and metabolic physiology.

This pathophysiology diagram illustrates the metabolic pathway of Vitamin D homeostasis and its associated genetic enzymes. The process begins with two sources: endogenous synthesis in the skin via Sunlight (UV-B) converting 7-DHC to PreD3 and then to Vitamin D3 (Cholecalciferol) through heat, and dietary intake (Vitamin D2 and D3). These converge into 'Calciferols'. The primary activation pathway shows the liver enzyme CYP2R1 hydroxylating calciferols into 25(OH)D (Calcidiol). This metabolite then moves to the kidney, where CYP27B1 converts it to the active form, 1,25(OH)2D (Calcitriol), which binds to the Vitamin D Receptor (VDR). The diagram also highlights catabolic inactivation pathways: in the kidney, CYP24A1 converts 25(OH)D and 1,25(OH)2D into inactive products (24,25(OH)2D and 1,24,25(OH)3D respectively). In the liver, CYP3A4 facilitates an alternative inactivation route, producing 4β,25(OH)2D and 1,23R,25(OH)3D. Key genes involved in Vitamin D-Dependent Rickets (VDDR) are highlighted in bold, emphasizing the clinical significance of these enzymatic steps in mineral metabolism.

This pathophysiology diagram illustrates the metabolic pathway of Vitamin D homeostasis and its associated genetic enzymes. The process begins with two sources: endogenous synthesis in the skin via Sunlight (UV-B) converting 7-DHC to PreD3 and then to Vitamin D3 (Cholecalciferol) through heat, and dietary intake (Vitamin D2 and D3). These converge into 'Calciferols'. The primary activation pathway shows the liver enzyme CYP2R1 hydroxylating calciferols into 25(OH)D (Calcidiol). This metabolite then moves to the kidney, where CYP27B1 converts it to the active form, 1,25(OH)2D (Calcitriol), which binds to the Vitamin D Receptor (VDR). The diagram also highlights catabolic inactivation pathways: in the kidney, CYP24A1 converts 25(OH)D and 1,25(OH)2D into inactive products (24,25(OH)2D and 1,24,25(OH)3D respectively). In the liver, CYP3A4 facilitates an alternative inactivation route, producing 4β,25(OH)2D and 1,23R,25(OH)3D. Key genes involved in Vitamin D-Dependent Rickets (VDDR) are highlighted in bold, emphasizing the clinical significance of these enzymatic steps in mineral metabolism.

This pathophysiology diagram illustrates the metabolic pathway of Vitamin D synthesis and activation in humans, emphasizing its role in immune modulation. The flow begins with two primary sources: endogenous synthesis in the skin (UVB radiation converting 7-dehydrocholesterol to Previtamin D3 and subsequently Vitamin D3) and exogenous intake (dietary sources like fish, eggs, and mushrooms or supplementation). The pathway then details the two-step hydroxylation process: first in the liver, where Vitamin D-25 hydroxylase (CYP2R1) converts Vitamin D3 into 25-hydroxyvitamin D3; and second in the kidney, where 1α-hydroxylase (CYP27B1) converts it into the bioactive form, 1,25-dihydroxyvitamin D3. The diagram concludes by highlighting the clinical significance of active Vitamin D in promoting immune regulation and anti-inflammatory activities, specifically questioning its potential protective effects against SARS-CoV-2. This schematic serves as an educational tool for understanding endocrine metabolism and its systemic physiological impacts.

This pathophysiology diagram illustrates the metabolic pathway of Vitamin D synthesis and activation in humans, emphasizing its role in immune modulation. The flow begins with two primary sources: endogenous synthesis in the skin (UVB radiation converting 7-dehydrocholesterol to Previtamin D3 and subsequently Vitamin D3) and exogenous intake (dietary sources like fish, eggs, and mushrooms or supplementation). The pathway then details the two-step hydroxylation process: first in the liver, where Vitamin D-25 hydroxylase (CYP2R1) converts Vitamin D3 into 25-hydroxyvitamin D3; and second in the kidney, where 1α-hydroxylase (CYP27B1) converts it into the bioactive form, 1,25-dihydroxyvitamin D3. The diagram concludes by highlighting the clinical significance of active Vitamin D in promoting immune regulation and anti-inflammatory activities, specifically questioning its potential protective effects against SARS-CoV-2. This schematic serves as an educational tool for understanding endocrine metabolism and its systemic physiological impacts.

Educational infographics depicting metabolic pathway analysis in a liver fibrosis model. Panel C presents a detailed pathophysiology diagram of regulated metabolic networks. Metabolites are color-coded by pathway: green for taurine and hypotaurine metabolism; light blue for arginine and proline; yellow for tryptophan; orange for phenylalanine; purple for sphingolipids; and pink for primary bile acid biosynthesis. Key metabolic conversions connect substances like cholesterol, primary bile acids, and taurine, illustrating the cross-talk between the TCA cycle and amino acid metabolism. White boxes indicate undetected metabolites. Panel D shows a circular metabolic network graph where individual metabolites are represented as nodes. The nodes are interconnected by gray lines representing functional relationships. A color scale indicates the uncorrected p-value (ranging from blue/0.7 to red/0), and node size reflects the magnitude of the measured value. This visual set demonstrates how experimental treatments influence specific metabolic signatures in hepatic disease research.

Educational infographics depicting metabolic pathway analysis in a liver fibrosis model. Panel C presents a detailed pathophysiology diagram of regulated metabolic networks. Metabolites are color-coded by pathway: green for taurine and hypotaurine metabolism; light blue for arginine and proline; yellow for tryptophan; orange for phenylalanine; purple for sphingolipids; and pink for primary bile acid biosynthesis. Key metabolic conversions connect substances like cholesterol, primary bile acids, and taurine, illustrating the cross-talk between the TCA cycle and amino acid metabolism. White boxes indicate undetected metabolites. Panel D shows a circular metabolic network graph where individual metabolites are represented as nodes. The nodes are interconnected by gray lines representing functional relationships. A color scale indicates the uncorrected p-value (ranging from blue/0.7 to red/0), and node size reflects the magnitude of the measured value. This visual set demonstrates how experimental treatments influence specific metabolic signatures in hepatic disease research.

Now let me read more of the Lippincott Biochemistry section on cortisol and also pull the Guyton section on cortisol effects.
Reading File
Reading File
Finding Sources
Searching Images

cortisol cortisone interconversion 11-beta hydroxysteroid dehydrogenase salivary gland kidney mineralocorticoid receptor

A comprehensive medical diagram illustrating the hypothalamic-pituitary-adrenal (HPA) and hypothalamic-pituitary-gonadal (HPG) axes, detailing the mechanism of action for prostate cancer pharmacotherapies. The illustration shows the hypothalamus releasing CRH and GnRH, which stimulate the anterior pituitary gland to secrete ACTH and gonadotropins (FSH/LH), respectively. These hormones target the adrenal glands and testes to produce androgens and cortisol. Key pharmacological interventions are indicated by inhibitory icons: abiraterone (inhibiting CYP17A1), exogenous prednisone (providing negative feedback to suppress ACTH), degarelix (GnRH antagonist), and androgen receptor antagonists like enzalutamide acting on the prostate. A central focus is the pathophysiology of secondary mineralocorticoid excess: the diagram traces how inhibition of steroidogenesis leads to deoxycorticosterone accumulation, affecting the nephron. Visible renal outcomes include sodium and water retention, potassium excretion (hypokalemia), and clinical hypertension. The diagram includes a legend identifying mineralocorticoid receptor antagonists (spironolactone/eplerenone) as agents used to mitigate these electrolyte imbalances.

A comprehensive medical diagram illustrating the hypothalamic-pituitary-adrenal (HPA) and hypothalamic-pituitary-gonadal (HPG) axes, detailing the mechanism of action for prostate cancer pharmacotherapies. The illustration shows the hypothalamus releasing CRH and GnRH, which stimulate the anterior pituitary gland to secrete ACTH and gonadotropins (FSH/LH), respectively. These hormones target the adrenal glands and testes to produce androgens and cortisol. Key pharmacological interventions are indicated by inhibitory icons: abiraterone (inhibiting CYP17A1), exogenous prednisone (providing negative feedback to suppress ACTH), degarelix (GnRH antagonist), and androgen receptor antagonists like enzalutamide acting on the prostate. A central focus is the pathophysiology of secondary mineralocorticoid excess: the diagram traces how inhibition of steroidogenesis leads to deoxycorticosterone accumulation, affecting the nephron. Visible renal outcomes include sodium and water retention, potassium excretion (hypokalemia), and clinical hypertension. The diagram includes a legend identifying mineralocorticoid receptor antagonists (spironolactone/eplerenone) as agents used to mitigate these electrolyte imbalances.

Summary : This flowchart outlines the clinical management process for starting mineralocorticoid receptor antagonist (MRA) therapy in patients with primary aldosteronism (PA), focusing on blood pressure, potassium, kidney function, and renin monitoring, and subsequent medication adjustments.

flowchart:
# Nodes :
  • Starting MRA in PA (rectangle): With MRA initiation, consider hypertension severity and stop/reduce other anti-hypertensive medications if appropriate; stop K supplements within 2–4 days of MRA initiation unless severely hypokalemic; recommend low sodium diet.
  • Primary Goals, in Priority Order (rectangle): Blood pressure controlled; reduction of unnecessary other anti-hypertensive medications; normokalemia; non-suppressed renin.
  • Check BP, Potassium, Kidney Function, and Renin (rectangle): 2–3 months or sooner if clinically indicated.
  • BP Uncontrolled and Renin Not Suppressed (rectangle): Add/Increase Non-MRA Anti-Hypertensive Medication.
  • BP Uncontrolled and Renin Suppressed OR Persistent Hypokalemia (rectangle): Increase MRA Dose.
  • BP Controlled (rectangle): Branches into two sub-nodes:
      – Renin Suppressed and other Non-MRA Anti-hypertensive Medications in Use (rectangle): MRA Dose Increase; Stop/Reduce Non-MRA Anti-hypertensive Medications as Appropriate.
      – Renin Normal/Increased vs Baseline (rectangle): Routine Follow-up.

# Connectors :
  • Downward arrows connect each step in the process, starting from "Starting MRA in PA" to "Primary Goals" to "Check BP, Potassium, Kidney Function, and Renin".
  • From "Check BP, Potassium, Kidney Function, and Renin", three branches lead to:
      – "BP Uncontrolled and Renin Not Suppressed"
      – "BP Uncontrolled and Renin Suppressed OR Persistent Hypokalemia"
      – "BP Controlled"
  • "BP Controlled" further branches into two sub-nodes based on renin status.

# Layout :
  • Vertical flow from top (starting MRA) to bottom (medication adjustment/follow-up).
  • At the decision point (Check BP, Potassium, Kidney Function, and Renin), the flow splits horizontally into three main branches, with the rightmost branch further splitting into two sub-branches.

# Analysis :
  • The flowchart provides a structured approach for clinicians to titrate MRA therapy and other anti-hypertensive medications based on blood pressure control, renin levels, and potassium status.
  • The process prioritizes blood pressure control, minimizing unnecessary medications, and achieving normokalemia and non-suppressed renin.
  • Decision points are clearly defined, allowing for tailored adjustments in therapy and follow-up based on patient response.
  • The chart emphasizes regular monitoring and timely intervention to optimize outcomes in PA management.

Summary : This flowchart outlines the clinical management process for starting mineralocorticoid receptor antagonist (MRA) therapy in patients with primary aldosteronism (PA), focusing on blood pressure, potassium, kidney function, and renin monitoring, and subsequent medication adjustments. flowchart: # Nodes : • Starting MRA in PA (rectangle): With MRA initiation, consider hypertension severity and stop/reduce other anti-hypertensive medications if appropriate; stop K supplements within 2–4 days of MRA initiation unless severely hypokalemic; recommend low sodium diet. • Primary Goals, in Priority Order (rectangle): Blood pressure controlled; reduction of unnecessary other anti-hypertensive medications; normokalemia; non-suppressed renin. • Check BP, Potassium, Kidney Function, and Renin (rectangle): 2–3 months or sooner if clinically indicated. • BP Uncontrolled and Renin Not Suppressed (rectangle): Add/Increase Non-MRA Anti-Hypertensive Medication. • BP Uncontrolled and Renin Suppressed OR Persistent Hypokalemia (rectangle): Increase MRA Dose. • BP Controlled (rectangle): Branches into two sub-nodes: – Renin Suppressed and other Non-MRA Anti-hypertensive Medications in Use (rectangle): MRA Dose Increase; Stop/Reduce Non-MRA Anti-hypertensive Medications as Appropriate. – Renin Normal/Increased vs Baseline (rectangle): Routine Follow-up. # Connectors : • Downward arrows connect each step in the process, starting from "Starting MRA in PA" to "Primary Goals" to "Check BP, Potassium, Kidney Function, and Renin". • From "Check BP, Potassium, Kidney Function, and Renin", three branches lead to: – "BP Uncontrolled and Renin Not Suppressed" – "BP Uncontrolled and Renin Suppressed OR Persistent Hypokalemia" – "BP Controlled" • "BP Controlled" further branches into two sub-nodes based on renin status. # Layout : • Vertical flow from top (starting MRA) to bottom (medication adjustment/follow-up). • At the decision point (Check BP, Potassium, Kidney Function, and Renin), the flow splits horizontally into three main branches, with the rightmost branch further splitting into two sub-branches. # Analysis : • The flowchart provides a structured approach for clinicians to titrate MRA therapy and other anti-hypertensive medications based on blood pressure control, renin levels, and potassium status. • The process prioritizes blood pressure control, minimizing unnecessary medications, and achieving normokalemia and non-suppressed renin. • Decision points are clearly defined, allowing for tailored adjustments in therapy and follow-up based on patient response. • The chart emphasizes regular monitoring and timely intervention to optimize outcomes in PA management.

Comparison of salivary gland imaging using 68Ga-PSMA-11 PET/CT and 99mTcO4− salivary gland scintigraphy (SGS) in a 64-year-old male with post-radiotherapy nasopharyngeal carcinoma. Panel (a) shows a Maximum Intensity Projection (MIP) image where a slight tracer uptake is noted in the right submandibular gland (small arrow, SUVmax 2.6). Panel (b) depicts planar SGS with absent tracer uptake in bilateral submandibular glands, indicating severe functional impairment. Panels (c-e) provide tomographic axial views (PET, CT, and fused PET/CT) illustrating morphological and functional asymmetry. There is a significant reduction in the volume (atrophy) of the left submandibular gland (large arrow, SUVmax 1.9) compared to the right. The diagnostic images demonstrate the superior sensitivity and anatomical resolution of 68Ga-PSMA-11 PET/CT over SGS in evaluating glandular atrophy and residual functional metabolic activity in salivary glands following radiotherapy.

Comparison of salivary gland imaging using 68Ga-PSMA-11 PET/CT and 99mTcO4− salivary gland scintigraphy (SGS) in a 64-year-old male with post-radiotherapy nasopharyngeal carcinoma. Panel (a) shows a Maximum Intensity Projection (MIP) image where a slight tracer uptake is noted in the right submandibular gland (small arrow, SUVmax 2.6). Panel (b) depicts planar SGS with absent tracer uptake in bilateral submandibular glands, indicating severe functional impairment. Panels (c-e) provide tomographic axial views (PET, CT, and fused PET/CT) illustrating morphological and functional asymmetry. There is a significant reduction in the volume (atrophy) of the left submandibular gland (large arrow, SUVmax 1.9) compared to the right. The diagnostic images demonstrate the superior sensitivity and anatomical resolution of 68Ga-PSMA-11 PET/CT over SGS in evaluating glandular atrophy and residual functional metabolic activity in salivary glands following radiotherapy.

Now let me pull the key Guyton section on cortisol modulation (11β-HSD) and the Ganong section on apparent mineralocorticoid excess.
Reading File
Reading File
Reading File
I found the key diagram. Let me fetch it now along with reading the Brenner & Rector section on 11β-HSD2 in the kidney.
Loading Image
Reading File
Loading Image
I now have all the information needed for a comprehensive answer. Let me compile it.

Cortisol Metabolism: Complete Overview

1. Overview and Circulation

Cortisol (hydrocortisone) is a glucocorticoid steroid secreted by the zona fasciculata of the adrenal cortex under ACTH stimulation. Once secreted, approximately 90-95% circulates bound to plasma proteins - primarily cortisol-binding globulin (CBG/transcortin) and albumin, with only ~5% as free, biologically active hormone. CBG is synthesized by the liver, so liver disease reduces bound cortisol and can affect interpretation of total plasma cortisol levels.
  • Guyton and Hall Textbook of Medical Physiology, pp. 950-954
  • Goldman-Cecil Medicine, p. 443

2. The Central Mechanism: 11β-Hydroxysteroid Dehydrogenase (11β-HSD)

The metabolism of cortisol at tissue level is governed by two isoforms of the enzyme 11β-hydroxysteroid dehydrogenase (11β-HSD), which interconvert active cortisol and inactive cortisone. This is the single most important pre-receptor regulatory mechanism for glucocorticoid action.
Interconversion of cortisol and cortisone by 11β-HSD1 and 11β-HSD2 in kidney, salivary glands, liver, and adipose tissue (Guyton Fig. 78.7)
Feature11β-HSD Type 111β-HSD Type 2
DirectionCortisone → Cortisol (reductase)Cortisol → Cortisone (dehydrogenase)
CofactorNADPH-dependentNAD⁺-dependent
Effect on cortisolActivates / amplifiesInactivates / protects
TissuesLiver, adipose tissue, brain, skin, skeletal muscle, lungKidney, colon, salivary glands, sweat glands, placenta
Clinical roleAmplifies glucocorticoid action locallyProtects mineralocorticoid receptor from cortisol
  • Guyton and Hall, pp. 953-954

3. Liver Metabolism

The liver has dual roles in cortisol metabolism:

A. 11β-HSD1 (Activation)

The liver highly expresses 11β-HSD1, which converts circulating inactive cortisone back to active cortisol. This amplifies intrahepatic glucocorticoid activity and drives:
  • Gluconeogenesis: Cortisol upregulates transcription of gluconeogenic enzymes (PEPCK, glucose-6-phosphatase). This can increase hepatic glucose output 6- to 10-fold.
  • Glycogen storage: Increased hepatic glycogen deposition.
  • Protein catabolism substrate supply: Mobilized amino acids from peripheral tissues are taken up by the liver for gluconeogenesis.

B. Hepatic Conjugation and Excretion (Terminal Catabolism)

The liver is the primary site of cortisol inactivation and elimination:
  1. Reduction: Ring A of cortisol is reduced by 5α-reductase and 5β-reductase, producing tetrahydrocortisol (THF) and allo-THF (5α-THF).
  2. Cortisone pathway: Cortisol → cortisone (via 11β-HSD2 in kidney) → tetrahydrocortisone (THE) via hepatic 5β-reductase and 3α-HSD.
  3. Glucuronide/sulfate conjugation: THF, allo-THF, and THE are conjugated with glucuronic acid (primarily) in the liver, making them water-soluble.
  4. Urinary excretion: These conjugates (collectively "urinary free cortisol metabolites") are excreted in urine.
The ratio (THF + allo-THF) : THE in urine reflects hepatic 11β-HSD1 activity. Elevated hepatic 11β-HSD1 (as in obesity) skews this ratio.
  • Biochemistry, Lippincott 8th ed, pp. 664-665
  • Goldman-Cecil Medicine

4. Kidney Metabolism

11β-HSD2 - The Mineralocorticoid Gatekeeper

The kidney (particularly the distal tubule and cortical collecting duct) expresses high levels of 11β-HSD2, which converts cortisol to inactive cortisone. This is physiologically essential because:
  • The mineralocorticoid receptor (MR) has equal affinity for both cortisol and aldosterone.
  • Circulating cortisol is ~1000× more abundant than aldosterone.
  • Without 11β-HSD2, cortisol would saturate all renal MRs and produce massive sodium retention and hypertension.
  • 11β-HSD2 ensures that only aldosterone can activate MRs in the kidney, allowing proper sodium/potassium homeostasis.

Mechanism:

Cortisol → (11β-HSD2, NAD⁺ dependent) → Cortisone (cannot bind MR)
Cortisone is then excreted as its tetrahydro-metabolite (THE).

Clinical Correlation - Apparent Mineralocorticoid Excess (AME):

When 11β-HSD2 is absent or inhibited:
  • Cortisol floods renal MRs → acts like aldosterone
  • Result: severe hypertension, hypokalemia, metabolic alkalosis, suppressed renin/aldosterone
  • Causes: genetic mutations in HSD11B2 gene, or licorice abuse (glycyrrhetinic acid is a suicide substrate for 11β-HSD2)
  • Urinary marker: elevated urinary free cortisol : cortisone (UFF:UFE) ratio - the best indicator of renal 11β-HSD2 activity
  • Guyton and Hall, p. 953; Brenner & Rector's The Kidney, p. 647; Ganong's Review, p. 3287

5. Salivary Gland Metabolism

Salivary glands also express 11β-HSD2, which converts cortisol → cortisone in the glandular epithelium. This has two important implications:
  1. Physiological: Protects salivary MRs (which regulate Na⁺/K⁺ transport in saliva) from cortisol excess.
  2. Diagnostic relevance: Salivary fluid contains both cortisol and cortisone. The salivary cortisol:cortisone ratio reflects local 11β-HSD2 activity. Unlike serum cortisol (which measures bound + free), salivary cortisol measures only free (bioactive) cortisol, making it an excellent non-invasive test for:
    • Cushing's syndrome (late-night salivary cortisol is a validated screening test)
    • HPA axis activity assessment, especially in children and research settings
    • Monitoring cortisol in neonates and during stress studies
When 11β-HSD2 is overwhelmed (e.g., Cushing's with very high cortisol), excess cortisol escapes inactivation in salivary gland tissue, and the salivary cortisol:cortisone ratio rises.

6. Metabolic Effects of Cortisol (Summary by Organ)

Systemic effects of cortisol on glucose metabolism across liver, muscle, pancreas, and adipose tissue
TissueEffect
Liver↑ Gluconeogenesis, ↑ glycogen storage, ↑ gluconeogenic enzyme transcription
Skeletal muscle↓ Glucose uptake (↓ GLUT4), ↑ protein catabolism → amino acids for liver
Adipose tissue↑ Lipolysis → FFA release, ↓ glucose uptake; central fat redistribution
Pancreas↓ Insulin sensitivity; ↑ β-cell compensation (chronic)
KidneyCortisol → cortisone (11β-HSD2); protects MR; regulates ENaC
Salivary glandsCortisol → cortisone (11β-HSD2); free cortisol in saliva = diagnostic biomarker
Immune cells↓ Prostaglandins, leukotrienes; lysosomal stabilization; ↓ capillary permeability
  • Guyton and Hall, pp. 2053-2071

7. Synthesis and Fate Pathway (Summary)

Cholesterol
    ↓ (StAR, CYP11A1)
Pregnenolone → Progesterone → 17α-OH-Progesterone → 11-Deoxycortisol
    ↓ (CYP11B1 - adrenal)
CORTISOL (active)
    ↓                               ↓
  KIDNEY/SALIVARY (11β-HSD2)     LIVER (11β-HSD1)
  Cortisol → Cortisone            Cortisone → Cortisol (amplification)
       ↓                               ↓
  [MR protected]            5α/5β-reductase + 3α-HSD
                              ↓
              THF / allo-THF (cortisol metabolites)
              THE (cortisone metabolite)
                              ↓
              Glucuronide conjugation (liver)
                              ↓
              Urinary excretion

Key Diagnostic Ratios

RatioReflectsUsed for
(THF + allo-THF) : THE in urineHepatic 11β-HSD1 activityObesity, metabolic syndrome research
UFF : UFE (urinary free cortisol : cortisone)Renal 11β-HSD2 activityAME diagnosis, licorice toxicity
Salivary cortisol (free)HPA axis, free cortisolCushing's screening (late-night)
Salivary cortisol : cortisoneSalivary gland 11β-HSD2 activityResearch, pediatric stress studies

Sources: Guyton and Hall Textbook of Medical Physiology (pp. 950-954); Lippincott's Illustrated Reviews: Biochemistry 8th ed (pp. 664-665); Brenner & Rector's The Kidney (p. 647); Ganong's Review of Medical Physiology (p. 3287); Goldman-Cecil Medicine; Wikipedia on 11β-HSD

can u make a flow chart

Generating Image

A detailed medical flowchart showing cortisol metabolism across different organs. The flowchart starts at the top with "Cholesterol" in the adrenal gland, flowing down through enzymatic steps (StAR, CYP11A1, CYP17, CYP21, CYP11B1) to produce "CORTISOL (Active)" in the zona fasciculata. From cortisol, the chart branches into three parallel pathways going left, center-right, and right: LEFT BRANCH - labeled "KIDNEY, SALIVARY GLANDS, Colon, Sweat Glands": Cortisol is acted on by 11β-HSD2 (NAD+ dependent, oxidase) → produces Cortisone (Inactive) → this PROTECTS Mineralocorticoid Receptor (MR) from cortisol → shown with a red X blocking MR activation. Note: "Only aldosterone activates MR". Clinical box: "If 11β-HSD2 deficient → AME: hypertension, hypokalemia. Licorice (glycyrrhetinic acid) inhibits 11β-HSD2" CENTER-RIGHT BRANCH - labeled "LIVER (primary catabolism)": Cortisol → 5α-reductase / 5β-reductase → Dihydrocortisol → 3α-HSD → Tetrahydrocortisol (THF) and allo-THF. Also: Cortisone → 5β-reductase → Tetrahydrocortisone (THE). Both THF/allo-THF and THE → Glucuronide conjugation (liver) → Urinary excretion. Diagnostic ratio box: "(THF + allo-THF) : THE = hepatic 11β-HSD1 activity" RIGHT BRANCH - labeled "LIVER, ADIPOSE, BRAIN, SKIN": Cortisone (inactive) → 11β-HSD1 (NADPH dependent, reductase) → Cortisol (active) → Glucocorticoid Receptor (GR) → Metabolic effects box listing: "↑ Gluconeogenesis, ↑ Glycogen storage, ↑ Protein catabolism, ↑ Lipolysis, ↓ Immune response" SALIVARY box at bottom: "Salivary Cortisol = FREE cortisol only → Diagnostic use: Late-night salivary cortisol for Cushing's screening. Salivary cortisol:cortisone ratio = 11β-HSD2 activity" Use color coding: yellow for cortisol, grey for cortisone, green for active states, red for blocked pathways. Clean professional medical diagram style with clear arrows and labeled boxes.

Cortisol Metabolism Flowchart
Here is the full cortisol metabolism flowchart. It covers:
  • Top: Synthesis from cholesterol in the adrenal cortex (zona fasciculata) through the CYP enzyme cascade
  • Left branch: Kidney, salivary glands, colon, and sweat glands - where 11β-HSD2 converts cortisol → inactive cortisone, protecting the mineralocorticoid receptor (with the AME/licorice clinical note)
  • Center branch: Hepatic catabolism through 5α/5β-reductase and 3α-HSD producing THF, allo-THF, and THE, followed by glucuronide conjugation and urinary excretion
  • Right branch: Liver, adipose, brain - where 11β-HSD1 reactivates cortisone → cortisol, amplifying glucocorticoid effects via the glucocorticoid receptor
  • Bottom: Salivary cortisol as a free-cortisol biomarker for Cushing's screening

no i want a simple one and in a ppt and all th ereferbces '

Reading File
Reading File
Running Command

mkdir -p /tmp/workspace/cortisol-ppt && ls /tmp/workspace/cortisol-ppt/

Writing File

~/cortisol-ppt/build_ppt.py

from pptx import Presentation
from pptx.util import Inches, Pt, Emu
from pptx.dml.color import RGBColor
from pptx.enum.text import PP_ALIGN, MSO_ANCHOR
from pptx.util import Inches, Pt
import copy

prs = Presentation()
prs.slide_width  = Inches(13.333)
prs.slide_height = Inches(7.5)
blank = prs.slide_layouts[6]

# ── Colour palette ──────────────────────────────────────────────
C_TITLE_BG   = RGBColor(0x1A, 0x3A, 0x5C)   # dark navy
C_TITLE_FG   = RGBColor(0xFF, 0xFF, 0xFF)
C_ACCENT     = RGBColor(0xF0, 0x A0, 0x00)   # amber accent bar
C_BOX_YELLOW = RGBColor(0xFF, 0xF0, 0xB0)    # cortisol box
C_BOX_GREY   = RGBColor(0xE0, 0xE0, 0xE0)    # cortisone box
C_BOX_GREEN  = RGBColor(0xC8, 0xE6, 0xC9)    # active/effect box
C_BOX_RED    = RGBColor(0xFF, 0xCC, 0xCC)    # AME/clinical box
C_BOX_BLUE   = RGBColor(0xBB, 0xDE, 0xFB)    # salivary / diag box
C_BOX_BORDER = RGBColor(0x33, 0x33, 0x33)
C_ARROW      = RGBColor(0x33, 0x33, 0x33)
C_REF_BG     = RGBColor(0xF5, 0xF5, 0xF5)
C_REF_TXT    = RGBColor(0x44, 0x44, 0x44)
C_WHITE      = RGBColor(0xFF, 0xFF, 0xFF)

# ── Helper: add a filled rectangle with centred text ────────────
def add_box(slide, x, y, w, h, fill_rgb, text, font_size=13,
            bold=False, font_rgb=RGBColor(0x11,0x11,0x11),
            border_rgb=C_BOX_BORDER, border_pt=1.0):
    shape = slide.shapes.add_shape(
        1,  # MSO_SHAPE_TYPE.RECTANGLE
        Inches(x), Inches(y), Inches(w), Inches(h)
    )
    shape.fill.solid()
    shape.fill.fore_color.rgb = fill_rgb
    shape.line.color.rgb = border_rgb
    shape.line.width = Pt(border_pt)
    tf = shape.text_frame
    tf.word_wrap = True
    tf.vertical_anchor = MSO_ANCHOR.MIDDLE
    p = tf.paragraphs[0]
    p.alignment = PP_ALIGN.CENTER
    run = p.add_run()
    run.text = text
    run.font.size = Pt(font_size)
    run.font.bold = bold
    run.font.color.rgb = font_rgb
    return shape

# ── Helper: add arrow (connector line with arrowhead) ───────────
def add_arrow(slide, x1, y1, x2, y2):
    from pptx.oxml.ns import qn
    from lxml import etree
    cx = int((x2 - x1) * 914400)
    cy = int((y2 - y1) * 914400)
    sp_tree = slide.shapes._spTree
    xml = f"""
    <p:cxnSp xmlns:p="http://schemas.openxmlformats.org/presentationml/2006/main"
             xmlns:a="http://schemas.openxmlformats.org/drawingml/2006/main"
             xmlns:r="http://schemas.openxmlformats.org/officeDocument/2006/relationships">
      <p:nvCxnSpPr>
        <p:cNvPr id="99" name="Arrow"/>
        <p:cNvCxnSpPr/>
        <p:nvPr/>
      </p:nvCxnSpPr>
      <p:spPr>
        <a:xfrm>
          <a:off x="{int(x1*914400)}" y="{int(y1*914400)}"/>
          <a:ext cx="{cx}" cy="{cy}"/>
        </a:xfrm>
        <a:prstGeom prst="straightConnector1"><a:avLst/></a:prstGeom>
        <a:ln w="25400">
          <a:solidFill><a:srgbClr val="333333"/></a:solidFill>
          <a:headEnd type="none"/>
          <a:tailEnd type="arrow" w="med" len="med"/>
        </a:ln>
      </p:spPr>
    </p:cxnSp>"""
    sp_tree.append(etree.fromstring(xml))

# ── Helper: slide-wide background ────────────────────────────────
def set_bg(slide, rgb):
    from pptx.oxml.ns import qn
    from lxml import etree
    bg = slide.background
    fill = bg.fill
    fill.solid()
    fill.fore_color.rgb = rgb

# ── Helper: text label (no box) ─────────────────────────────────
def add_label(slide, x, y, w, h, text, size=11, bold=False,
              align=PP_ALIGN.CENTER, rgb=RGBColor(0x33,0x33,0x33)):
    tb = slide.shapes.add_textbox(Inches(x), Inches(y), Inches(w), Inches(h))
    tf = tb.text_frame
    tf.word_wrap = True
    tf.vertical_anchor = MSO_ANCHOR.MIDDLE
    p = tf.paragraphs[0]
    p.alignment = align
    run = p.add_run()
    run.text = text
    run.font.size = Pt(size)
    run.font.bold = bold
    run.font.color.rgb = rgb

# ══════════════════════════════════════════════════════════════════
# SLIDE 1 — Title slide
# ══════════════════════════════════════════════════════════════════
s1 = prs.slides.add_slide(blank)
set_bg(s1, RGBColor(0xF7, 0xF9, 0xFF))

# navy header bar
hdr = s1.shapes.add_shape(1, Inches(0), Inches(0), Inches(13.333), Inches(2.2))
hdr.fill.solid(); hdr.fill.fore_color.rgb = C_TITLE_BG
hdr.line.fill.background()

add_label(s1, 0.3, 0.25, 12.7, 1.1,
          "CORTISOL METABOLISM", size=40, bold=True, rgb=C_TITLE_FG)
add_label(s1, 0.3, 1.3, 12.7, 0.7,
          "Liver  |  Kidney  |  Salivary Glands  |  Peripheral Tissues",
          size=18, rgb=RGBColor(0xBB, 0xCC, 0xFF))

add_label(s1, 1.5, 2.5, 10, 0.5,
          "Cortisol is secreted by the zona fasciculata of the adrenal cortex in response to ACTH.",
          size=14, rgb=RGBColor(0x22,0x22,0x55))
add_label(s1, 1.5, 3.1, 10, 0.5,
          "~90–95% circulates BOUND to cortisol-binding globulin (CBG) and albumin (liver-synthesised).",
          size=14, rgb=RGBColor(0x22,0x22,0x55))
add_label(s1, 1.5, 3.7, 10, 0.5,
          "~5% is FREE — the biologically active fraction.",
          size=14, rgb=RGBColor(0x22,0x22,0x55))
add_label(s1, 1.5, 4.3, 10, 0.5,
          "Key enzyme: 11β-Hydroxysteroid Dehydrogenase (11β-HSD) — two isoforms control tissue-level activity.",
          size=14, rgb=RGBColor(0x22,0x22,0x55))

# footer
add_label(s1, 0.2, 7.0, 12.9, 0.4,
          "References: Guyton & Hall (2021) p.950–954 | Lippincott Biochemistry 8e p.664–665 | Ganong's Review 26e p.3287 | Brenner & Rector's Kidney p.647 | Goldman-Cecil Medicine",
          size=8, rgb=RGBColor(0x88,0x88,0x88))

# ══════════════════════════════════════════════════════════════════
# SLIDE 2 — 11β-HSD isoforms comparison table
# ══════════════════════════════════════════════════════════════════
s2 = prs.slides.add_slide(blank)
set_bg(s2, RGBColor(0xF7, 0xF9, 0xFF))
hdr2 = s2.shapes.add_shape(1, Inches(0), Inches(0), Inches(13.333), Inches(1.2))
hdr2.fill.solid(); hdr2.fill.fore_color.rgb = C_TITLE_BG; hdr2.line.fill.background()
add_label(s2, 0.3, 0.1, 12.7, 0.9, "The 11β-HSD Enzyme System — Pre-receptor Gatekeeper",
          size=26, bold=True, rgb=C_TITLE_FG)

# Table headers
cols = ["Feature", "11β-HSD Type 1", "11β-HSD Type 2"]
col_x = [0.3, 3.5, 8.0]
col_w = [3.0, 4.3, 4.9]
row_data = [
    ("Direction",    "Cortisone → Cortisol\n(Reductase — ACTIVATES)",
                     "Cortisol → Cortisone\n(Dehydrogenase — INACTIVATES)"),
    ("Cofactor",     "NADPH-dependent",           "NAD⁺-dependent"),
    ("Tissues",      "Liver, Adipose, Brain,\nSkin, Skeletal muscle",
                     "Kidney, Salivary glands,\nColon, Sweat glands, Placenta"),
    ("Net Effect",   "Amplifies glucocorticoid\naction locally",
                     "Protects mineralocorticoid\nreceptor from cortisol"),
    ("Clinical relevance",
                     "↑ in obesity → insulin\nresistance; cognitive decline",
                     "Deficiency → Apparent\nMineralocorticoid Excess (AME)"),
]
header_fills = [RGBColor(0x1A,0x3A,0x5C), RGBColor(0x2E,0x7D,0x32), RGBColor(0xC6,0x28,0x28)]
header_fgs   = [C_WHITE, C_WHITE, C_WHITE]

for ci, (col, cx, cw) in enumerate(zip(cols, col_x, col_w)):
    add_box(s2, cx, 1.3, cw, 0.55, header_fills[ci], col,
            font_size=14, bold=True, font_rgb=header_fgs[ci],
            border_rgb=RGBColor(0xFF,0xFF,0xFF), border_pt=1.5)

row_fills = [C_BOX_YELLOW, C_BOX_GREY, C_BOX_GREEN, C_BOX_BLUE, C_BOX_RED]
for ri, (label, v1, v2) in enumerate(row_data):
    ry = 1.9 + ri * 0.98
    add_box(s2, 0.3,  ry, 3.0, 0.88, RGBColor(0xEE,0xEE,0xEE), label,
            font_size=12, bold=True)
    add_box(s2, 3.5,  ry, 4.3, 0.88, row_fills[ri], v1,  font_size=11)
    add_box(s2, 8.0,  ry, 4.9, 0.88, row_fills[ri], v2,  font_size=11)

add_label(s2, 0.2, 7.0, 12.9, 0.4,
          "References: Guyton & Hall (2021) p.953–954 | Wikipedia: 11β-Hydroxysteroid dehydrogenase | Brenner & Rector's Kidney p.647",
          size=8, rgb=RGBColor(0x88,0x88,0x88))

# ══════════════════════════════════════════════════════════════════
# SLIDE 3 — Simple Flowchart: Cortisol Metabolism
# ══════════════════════════════════════════════════════════════════
s3 = prs.slides.add_slide(blank)
set_bg(s3, RGBColor(0xF7, 0xF9, 0xFF))
hdr3 = s3.shapes.add_shape(1, Inches(0), Inches(0), Inches(13.333), Inches(1.1))
hdr3.fill.solid(); hdr3.fill.fore_color.rgb = C_TITLE_BG; hdr3.line.fill.background()
add_label(s3, 0.3, 0.1, 12.7, 0.85, "Cortisol Metabolism — Simple Flowchart",
          size=26, bold=True, rgb=C_TITLE_FG)

# Central cortisol box (top centre)
add_box(s3, 4.9, 1.2, 3.5, 0.75, C_BOX_YELLOW,
        "CORTISOL (Active)\nSecreted by Adrenal Cortex", font_size=12, bold=True)

# Arrow down-left to Kidney branch
add_arrow(s3, 5.0, 1.95, 2.2, 3.0)
# Arrow down-right to Liver/HSD1 branch
add_arrow(s3, 8.3, 1.95, 11.1, 3.0)
# Arrow straight down to Liver catabolism
add_arrow(s3, 6.65, 1.95, 6.65, 3.0)

# ── LEFT: Kidney / Salivary ──────────────────────────────────────
add_box(s3, 0.3, 3.0, 3.8, 0.75, C_BOX_BLUE,
        "Kidney | Salivary Glands\nColon | Sweat Glands", font_size=11, bold=True)
add_arrow(s3, 2.2, 3.75, 2.2, 4.5)
add_label(s3, 0.3, 3.78, 3.8, 0.65, "11β-HSD2\n(NAD⁺, Dehydrogenase)", size=10,
          rgb=RGBColor(0x77,0x00,0x00))
add_box(s3, 0.3, 4.5, 3.8, 0.65, C_BOX_GREY,
        "CORTISONE (Inactive)", font_size=12, bold=True)
add_arrow(s3, 2.2, 5.15, 2.2, 5.85)
add_box(s3, 0.3, 5.85, 3.8, 0.75, C_BOX_RED,
        "MR PROTECTED\n✗ Cannot activate Mineralocorticoid Receptor", font_size=10)

# ── CENTRE: Liver catabolism ─────────────────────────────────────
add_box(s3, 4.9, 3.0, 3.5, 0.7, C_BOX_YELLOW,
        "LIVER (Catabolism)", font_size=12, bold=True)
add_arrow(s3, 6.65, 3.7, 6.65, 4.4)
add_label(s3, 4.9, 3.72, 3.5, 0.65,
          "5α/5β-Reductase + 3α-HSD", size=10, rgb=RGBColor(0x00,0x55,0x00))
add_box(s3, 4.9, 4.4, 3.5, 0.7, C_BOX_GREEN,
        "THF / allo-THF / THE\n(Tetrahydro metabolites)", font_size=11)
add_arrow(s3, 6.65, 5.1, 6.65, 5.75)
add_label(s3, 4.9, 5.12, 3.5, 0.6,
          "Glucuronide conjugation", size=10, rgb=RGBColor(0x00,0x55,0x00))
add_box(s3, 4.9, 5.75, 3.5, 0.65, C_BOX_BLUE,
        "URINE EXCRETION\n(Water-soluble conjugates)", font_size=11)

# ── RIGHT: Liver HSD1 / Amplification ────────────────────────────
add_box(s3, 9.2, 3.0, 3.9, 0.75, C_BOX_GREY,
        "Liver | Adipose | Brain\nSkin | Skeletal Muscle", font_size=11, bold=True)
add_arrow(s3, 11.15, 3.75, 11.15, 4.45)
add_label(s3, 9.2, 3.78, 3.9, 0.65, "11β-HSD1\n(NADPH, Reductase — ACTIVATES)", size=10,
          rgb=RGBColor(0x00,0x44,0x88))
add_box(s3, 9.2, 4.45, 3.9, 0.7, C_BOX_YELLOW,
        "CORTISOL (Active)\n→ Glucocorticoid Receptor (GR)", font_size=11, bold=True)
add_arrow(s3, 11.15, 5.15, 11.15, 5.8)
add_box(s3, 9.2, 5.8, 3.9, 0.8, C_BOX_GREEN,
        "↑ Gluconeogenesis  ↑ Lipolysis\n↓ Immune response  ↑ Protein catabolism",
        font_size=10)

add_label(s3, 0.2, 7.0, 12.9, 0.4,
          "References: Guyton & Hall (2021) p.950–954 | Lippincott Biochemistry 8e p.664–665 | Ganong's Review 26e p.3287 | Brenner & Rector's Kidney p.647",
          size=8, rgb=RGBColor(0x88,0x88,0x88))

# ══════════════════════════════════════════════════════════════════
# SLIDE 4 — Kidney in detail
# ══════════════════════════════════════════════════════════════════
s4 = prs.slides.add_slide(blank)
set_bg(s4, RGBColor(0xF7, 0xF9, 0xFF))
hdr4 = s4.shapes.add_shape(1, Inches(0), Inches(0), Inches(13.333), Inches(1.1))
hdr4.fill.solid(); hdr4.fill.fore_color.rgb = C_TITLE_BG; hdr4.line.fill.background()
add_label(s4, 0.3, 0.1, 12.7, 0.85, "Kidney — Role of 11β-HSD2",
          size=26, bold=True, rgb=C_TITLE_FG)

points_kidney = [
    ("11β-HSD2 in distal tubule / cortical collecting duct",
     "Converts cortisol → cortisone (NAD⁺-dependent)"),
    ("Why it matters",
     "Cortisol circulates at ~1000× the concentration of aldosterone\nbut BOTH have equal affinity for the mineralocorticoid receptor (MR)"),
    ("Normal state",
     "11β-HSD2 inactivates cortisol → only aldosterone activates MR\n→ normal Na⁺ reabsorption, K⁺ excretion, blood pressure"),
    ("If 11β-HSD2 fails (AME / Licorice abuse)",
     "Cortisol floods MR → Na⁺ retention, hypertension, hypokalemia\nSuppressed renin, angiotensin II and aldosterone"),
    ("Diagnostic marker",
     "Urinary free cortisol : cortisone (UFF:UFE) ratio\n↑ ratio = impaired renal 11β-HSD2 activity"),
]

for i, (title, body) in enumerate(points_kidney):
    ry = 1.25 + i * 1.12
    add_box(s4, 0.4, ry, 4.5, 0.95, C_BOX_BLUE, title, font_size=12, bold=True)
    add_box(s4, 5.1, ry, 7.9, 0.95, C_BOX_GREY, body, font_size=11)

add_label(s4, 0.2, 7.0, 12.9, 0.4,
          "References: Guyton & Hall (2021) p.953 | Ganong's Review 26e p.3287 | Brenner & Rector's Kidney p.647 | Goldman-Cecil Medicine",
          size=8, rgb=RGBColor(0x88,0x88,0x88))

# ══════════════════════════════════════════════════════════════════
# SLIDE 5 — Liver in detail
# ══════════════════════════════════════════════════════════════════
s5 = prs.slides.add_slide(blank)
set_bg(s5, RGBColor(0xF7, 0xF9, 0xFF))
hdr5 = s5.shapes.add_shape(1, Inches(0), Inches(0), Inches(13.333), Inches(1.1))
hdr5.fill.solid(); hdr5.fill.fore_color.rgb = C_TITLE_BG; hdr5.line.fill.background()
add_label(s5, 0.3, 0.1, 12.7, 0.85, "Liver — Dual Role in Cortisol Metabolism",
          size=26, bold=True, rgb=C_TITLE_FG)

# Two columns
add_label(s5, 0.3, 1.15, 6.0, 0.5, "ROLE 1: ACTIVATION (11β-HSD1)",
          size=16, bold=True, rgb=RGBColor(0x1A,0x3A,0x5C))
add_label(s5, 7.0, 1.15, 6.0, 0.5, "ROLE 2: CATABOLISM & EXCRETION",
          size=16, bold=True, rgb=RGBColor(0x1A,0x3A,0x5C))

left_pts = [
    "Liver expresses 11β-HSD1 (NADPH reductase)",
    "Converts cortisone → active cortisol",
    "Amplifies glucocorticoid signalling locally",
    "↑ Gluconeogenesis (6–10× baseline)",
    "↑ Glycogen storage",
    "↑ Expression of gluconeogenic enzymes\n(PEPCK, G6Pase) via GR-mediated transcription",
    "↑ 11β-HSD1 in obesity → contributes to\ninsulin resistance & metabolic syndrome",
]
right_pts = [
    "5β-reductase (and 5α-reductase) reduce ring A",
    "→ Dihydrocortisol → Tetrahydrocortisol (THF)",
    "Cortisone → Tetrahydrocortisone (THE) via 5β-reductase",
    "Glucuronide (mainly) or sulfate conjugation",
    "Water-soluble conjugates excreted in urine",
    "Ratio (THF + allo-THF) : THE reflects\nhepatic 11β-HSD1 activity",
    "CBG (cortisol-binding globulin) also\nsynthesised by liver — liver disease ↓ CBG",
]

for i, pt in enumerate(left_pts):
    ry = 1.75 + i * 0.72
    b = s5.shapes.add_shape(1, Inches(0.3), Inches(ry), Inches(6.0), Inches(0.62))
    b.fill.solid(); b.fill.fore_color.rgb = C_BOX_YELLOW
    b.line.color.rgb = C_BOX_BORDER; b.line.width = Pt(0.75)
    tf = b.text_frame; tf.word_wrap = True; tf.vertical_anchor = MSO_ANCHOR.MIDDLE
    p = tf.paragraphs[0]; p.alignment = PP_ALIGN.LEFT
    run = p.add_run(); run.text = "• " + pt
    run.font.size = Pt(11); run.font.color.rgb = RGBColor(0x11,0x11,0x11)
    tf.margin_left = Pt(6)

for i, pt in enumerate(right_pts):
    ry = 1.75 + i * 0.72
    b = s5.shapes.add_shape(1, Inches(7.0), Inches(ry), Inches(6.1), Inches(0.62))
    b.fill.solid(); b.fill.fore_color.rgb = C_BOX_GREEN
    b.line.color.rgb = C_BOX_BORDER; b.line.width = Pt(0.75)
    tf = b.text_frame; tf.word_wrap = True; tf.vertical_anchor = MSO_ANCHOR.MIDDLE
    p = tf.paragraphs[0]; p.alignment = PP_ALIGN.LEFT
    run = p.add_run(); run.text = "• " + pt
    run.font.size = Pt(11); run.font.color.rgb = RGBColor(0x11,0x11,0x11)
    tf.margin_left = Pt(6)

add_label(s5, 0.2, 7.0, 12.9, 0.4,
          "References: Guyton & Hall (2021) p.2055–2071 | Lippincott Biochemistry 8e p.664–665 | Goldman-Cecil Medicine p.443",
          size=8, rgb=RGBColor(0x88,0x88,0x88))

# ══════════════════════════════════════════════════════════════════
# SLIDE 6 — Salivary Glands
# ══════════════════════════════════════════════════════════════════
s6 = prs.slides.add_slide(blank)
set_bg(s6, RGBColor(0xF7, 0xF9, 0xFF))
hdr6 = s6.shapes.add_shape(1, Inches(0), Inches(0), Inches(13.333), Inches(1.1))
hdr6.fill.solid(); hdr6.fill.fore_color.rgb = C_TITLE_BG; hdr6.line.fill.background()
add_label(s6, 0.3, 0.1, 12.7, 0.85, "Salivary Glands — Cortisol Metabolism & Diagnostic Use",
          size=26, bold=True, rgb=C_TITLE_FG)

sal_pts = [
    ("11β-HSD2 present in salivary gland epithelium",
     "Converts cortisol → cortisone\nProtects salivary mineralocorticoid receptors (regulate Na⁺/K⁺ in saliva)"),
    ("Salivary cortisol = FREE cortisol only",
     "Unlike serum (90–95% protein-bound)\nSaliva contains only the unbound, biologically active fraction"),
    ("Diagnostic — Late-night salivary cortisol",
     "Gold-standard non-invasive screen for Cushing's syndrome\nNormal: low at midnight; Cushing's: remains elevated"),
    ("Salivary cortisol : cortisone ratio",
     "Reflects local 11β-HSD2 activity\nHigh ratio = impaired inactivation (enzyme overwhelmed or deficient)"),
    ("Advantages of salivary sampling",
     "Non-invasive, stress-free, suitable for children, outpatients & research\nStable at room temperature for several hours"),
]

for i, (title, body) in enumerate(sal_pts):
    ry = 1.25 + i * 1.12
    add_box(s6, 0.4, ry, 4.5, 0.95, C_BOX_BLUE, title, font_size=12, bold=True)
    add_box(s6, 5.1, ry, 7.9, 0.95, C_BOX_GREY, body, font_size=11)

add_label(s6, 0.2, 7.0, 12.9, 0.4,
          "References: Guyton & Hall (2021) p.953 | Salivary Biomarkers Review, Univ. of Liverpool (2021) | Ganong's Review 26e p.3287",
          size=8, rgb=RGBColor(0x88,0x88,0x88))

# ══════════════════════════════════════════════════════════════════
# SLIDE 7 — Clinical Correlations
# ══════════════════════════════════════════════════════════════════
s7 = prs.slides.add_slide(blank)
set_bg(s7, RGBColor(0xF7, 0xF9, 0xFF))
hdr7 = s7.shapes.add_shape(1, Inches(0), Inches(0), Inches(13.333), Inches(1.1))
hdr7.fill.solid(); hdr7.fill.fore_color.rgb = C_TITLE_BG; hdr7.line.fill.background()
add_label(s7, 0.3, 0.1, 12.7, 0.85, "Clinical Correlations",
          size=26, bold=True, rgb=C_TITLE_FG)

clin = [
    ("Apparent Mineralocorticoid\nExcess (AME)",
     "Genetic deficiency of 11β-HSD2\nCortisol activates renal MR\nHypertension + Hypokalemia + Suppressed aldosterone",
     C_BOX_RED),
    ("Licorice Abuse",
     "Glycyrrhetinic acid inhibits 11β-HSD2\nSame picture as AME\nReversible on stopping licorice",
     C_BOX_RED),
    ("Cushing's Syndrome",
     "Extreme cortisol excess overwhelms 11β-HSD2\nCortisol spills into MR → Na⁺ retention\nAlso adrenal diabetes, central obesity",
     C_BOX_RED),
    ("Obesity / Metabolic Syndrome",
     "↑ Adipose 11β-HSD1 → excess local cortisol\nContributes to insulin resistance, dyslipidaemia\nTarget for drug development (11β-HSD1 inhibitors)",
     C_BOX_YELLOW),
    ("Cushing's Screening",
     "Late-night salivary cortisol — validated first-line test\nUrinary free cortisol / 24-hr UFC\nLow-dose dexamethasone suppression test",
     C_BOX_BLUE),
    ("Diagnostic Ratios",
     "(THF + allo-THF) : THE → hepatic 11β-HSD1\nUFF : UFE (urinary) → renal 11β-HSD2\nSalivary cortisol : cortisone → salivary 11β-HSD2",
     C_BOX_GREEN),
]

for i, (title, body, fill) in enumerate(clin):
    col = i % 2
    row = i // 2
    cx = 0.3 + col * 6.6
    ry = 1.2 + row * 2.0
    add_box(s7, cx, ry, 3.0, 1.7, C_TITLE_BG, title, font_size=13, bold=True,
            font_rgb=C_WHITE, border_rgb=C_WHITE)
    add_box(s7, cx + 3.1, ry, 3.4, 1.7, fill, body, font_size=10)

add_label(s7, 0.2, 7.0, 12.9, 0.4,
          "References: Ganong's Review 26e p.3287 | Brenner & Rector's Kidney p.647 | Guyton & Hall (2021) p.953–954 | Liverpool Salivary Biomarkers Review (2021)",
          size=8, rgb=RGBColor(0x88,0x88,0x88))

# ══════════════════════════════════════════════════════════════════
# SLIDE 8 — References
# ══════════════════════════════════════════════════════════════════
s8 = prs.slides.add_slide(blank)
set_bg(s8, RGBColor(0xF7, 0xF9, 0xFF))
hdr8 = s8.shapes.add_shape(1, Inches(0), Inches(0), Inches(13.333), Inches(1.1))
hdr8.fill.solid(); hdr8.fill.fore_color.rgb = C_TITLE_BG; hdr8.line.fill.background()
add_label(s8, 0.3, 0.1, 12.7, 0.85, "References", size=26, bold=True, rgb=C_TITLE_FG)

refs = [
    "1.  Hall JE, Hall ME. Guyton and Hall Textbook of Medical Physiology. 14th ed. Elsevier; 2021. pp. 950–954.",
    "2.  Ferrier DR. Lippincott Illustrated Reviews: Biochemistry. 8th ed. Wolters Kluwer; 2022. pp. 664–665.",
    "3.  Barrett KE, et al. Ganong's Review of Medical Physiology. 26th ed. McGraw-Hill; 2019. p. 3287.",
    "4.  Yu ASL, et al. Brenner and Rector's The Kidney. 11th ed. Elsevier; 2020. p. 647.",
    "5.  Goldman L, Schafer AI. Goldman-Cecil Medicine. 26th ed. Elsevier; 2020. Chapter 203.",
    "6.  Chapman K, Holmes M, Seckl J. 11β-Hydroxysteroid Dehydrogenases: Intracellular Gate-Keepers of\n    Tissue Glucocorticoid Action. Physiol Rev. 2013;93(3):1139–1206. PMC3962546.",
    "7.  New MI, et al. 11β-Hydroxysteroid Dehydrogenase and Its Role in Apparent Mineralocorticoid Excess.\n    Pediatr Res. 1997;41(1):25–29.",
    "8.  Clow A, et al. Salivary Biomarkers of Health and Disease from Childhood to Older Adults.\n    University of Liverpool Repository; 2021.",
    "9.  Wikipedia: 11β-Hydroxysteroid dehydrogenase. Accessed July 2026.\n    https://en.wikipedia.org/wiki/11%CE%B2-Hydroxysteroid_dehydrogenase",
]

for i, ref in enumerate(refs):
    ry = 1.2 + i * 0.67
    tb = s8.shapes.add_textbox(Inches(0.5), Inches(ry), Inches(12.5), Inches(0.6))
    tf = tb.text_frame; tf.word_wrap = True
    p = tf.paragraphs[0]; p.alignment = PP_ALIGN.LEFT
    run = p.add_run(); run.text = ref
    run.font.size = Pt(12); run.font.color.rgb = C_REF_TXT

# ══════════════════════════════════════════════════════════════════
# SAVE
# ══════════════════════════════════════════════════════════════════
out = "/tmp/workspace/cortisol-ppt/Cortisol_Metabolism.pptx"
prs.save(out)
print(f"Saved: {out}")
Running Command

cd /tmp/workspace/cortisol-ppt && python build_ppt.py 2>&1

Editing File

~/cortisol-ppt/build_ppt.py

Successfully replaced 1 instance(s) of the string in '/tmp/workspace/cortisol-ppt/build_ppt.py'
Running Command

cd /tmp/workspace/cortisol-ppt && python build_ppt.py 2>&1

Your presentation is ready!

Cortisol Metabolism

Presentation · PPTX


Here's what's inside the 8-slide deck:
SlideContent
1Title slide - overview of cortisol circulation & binding
211β-HSD isoforms comparison table (HSD1 vs HSD2)
3Simple flowchart - Cortisol → 3 branches: Kidney/Salivary, Liver catabolism, Liver/Adipose activation
4Kidney detail - 11β-HSD2, MR protection, AME, diagnostic ratio
5Liver detail - dual role: activation (HSD1) + catabolism (THF/THE → urine)
6Salivary glands - 11β-HSD2, free cortisol, Cushing's screening
7Clinical correlations - AME, licorice, Cushing's, obesity, diagnostic ratios
8Full references (9 sources)
All slides have a navy header with references in the footer. Let me know if you'd like any changes to colours, layout, or content!

i want put a slide on basis of investiation in Cushing syndrome gve me some bullet points

Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
I have all the information needed. Here are the bullet points, then I'll add the slide to the PPT.

Bullet Points: Investigation of Cushing's Syndrome

Here is the structured content organised in a logical clinical sequence:

STEP 1 — First exclude Iatrogenic Cushing's

  • Rule out exogenous corticosteroid use (oral, inhaled, topical)

STEP 2 — Screening Tests (confirm hypercortisolism)

(Endocrine Society 2008: at least 2 tests should be abnormal)
  • Late-night salivary cortisol (×2 measurements) - loss of diurnal rhythm; elevated at midnight = abnormal
  • 24-hour urinary free cortisol (UFC) (×2 measurements) - >3× upper limit of normal = significant overspill
  • Overnight 1-mg dexamethasone suppression test (DST) - morning cortisol >50 nmol/L (>1.8 µg/dL) = non-suppressed = abnormal
  • 2-mg 48-hour DST - preferred in depression, obesity, alcoholism, diabetes (pseudo-Cushing states)
  • Note: Use 24-hr UFC in pregnancy and severe renal failure (DST unreliable)

STEP 3 — Determine ACTH dependency (plasma ACTH)

  • ACTH elevated (>20 pg/mL) → ACTH-dependent (~80% of cases)
  • ACTH suppressed (<5 pg/mL) → ACTH-independent (~20% of cases)

STEP 4A — If ACTH-Dependent

  • Pituitary MRI - most have microadenoma (<10 mm); low sensitivity in isolation
  • High-dose DST (8 mg) - suppression >50% suggests Cushing's disease (pituitary); no suppression suggests ectopic
  • CRH stimulation test - exaggerated ACTH/cortisol rise = Cushing's disease
  • Bilateral inferior petrosal sinus sampling (BIPSS) - gold standard to distinguish pituitary vs ectopic ACTH; after CRH stimulation
  • If ectopic suspected: CT thorax/abdomen/pelvis; ⁶⁸Ga-SSTR PET-CT (75-80% sensitive for ectopic source)

STEP 4B — If ACTH-Independent

  • CT or MRI of adrenal glands - unilateral adenoma / bilateral hyperplasia / adrenocortical carcinoma
  • Benign adenoma: hypodense, <10 HU on non-contrast CT

Now adding this as a new slide to the PPT:
Running Command

cd /tmp/workspace/cortisol-ppt && python3 - <<'EOF' from pptx import Presentation from pptx.util import Inches, Pt from pptx.dml.color import RGBColor from pptx.enum.text import PP_ALIGN, MSO_ANCHOR from io import BytesIO prs = Presentation("Cortisol_Metabolism.pptx") blank = prs.slide_layouts[6] C_TITLE_BG = RGBColor(0x1A,0x3A,0x5C) C_WHITE = RGBColor(0xFF,0xFF,0xFF) C_BOX_BLUE = RGBColor(0xBB,0xDE,0xFB) C_BOX_YELLOW= RGBColor(0xFF,0xF0,0xB0) C_BOX_GREEN = RGBColor(0xC8,0xE6,0xC9) C_BOX_RED = RGBColor(0xFF,0xCC,0xCC) C_BOX_GREY = RGBColor(0xE8,0xE8,0xE8) C_BOX_ORANGE= RGBColor(0xFF,0xE0,0xB2) C_TXT = RGBColor(0x11,0x11,0x11) C_BORDER = RGBColor(0x55,0x55,0x55) def set_bg(slide, rgb): slide.background.fill.solid() slide.background.fill.fore_color.rgb = rgb def add_label(slide, x, y, w, h, text, size=12, bold=False, align=PP_ALIGN.LEFT, rgb=RGBColor(0x11,0x11,0x11)): tb = slide.shapes.add_textbox(Inches(x), Inches(y), Inches(w), Inches(h)) tf = tb.text_frame; tf.word_wrap = True tf.vertical_anchor = MSO_ANCHOR.MIDDLE p = tf.paragraphs[0]; p.alignment = align run = p.add_run(); run.text = text run.font.size = Pt(size); run.font.bold = bold run.font.color.rgb = rgb def add_box(slide, x, y, w, h, fill, text, fsize=11, bold=False, align=PP_ALIGN.LEFT, border=C_BORDER): shape = slide.shapes.add_shape(1, Inches(x), Inches(y), Inches(w), Inches(h)) shape.fill.solid(); shape.fill.fore_color.rgb = fill shape.line.color.rgb = border; shape.line.width = Pt(0.8) tf = shape.text_frame; tf.word_wrap = True tf.vertical_anchor = MSO_ANCHOR.MIDDLE tf.margin_left = Pt(6); tf.margin_right = Pt(4) p = tf.paragraphs[0]; p.alignment = align run = p.add_run(); run.text = text run.font.size = Pt(fsize); run.font.bold = bold run.font.color.rgb = C_TXT def add_arrow(slide, x1, y1, x2, y2): from lxml import etree sp_tree = slide.shapes._spTree xml = f"""<p:cxnSp xmlns:p="http://schemas.openxmlformats.org/presentationml/2006/main" xmlns:a="http://schemas.openxmlformats.org/drawingml/2006/main" xmlns:r="http://schemas.openxmlformats.org/officeDocument/2006/relationships"> <p:nvCxnSpPr><p:cNvPr id="200" name="Arr"/><p:cNvCxnSpPr/><p:nvPr/></p:nvCxnSpPr> <p:spPr> <a:xfrm><a:off x="{int(x1*914400)}" y="{int(y1*914400)}"/> <a:ext cx="{int((x2-x1)*914400)}" cy="{int((y2-y1)*914400)}"/></a:xfrm> <a:prstGeom prst="straightConnector1"><a:avLst/></a:prstGeom> <a:ln w="22860"><a:solidFill><a:srgbClr val="333333"/></a:solidFill> <a:headEnd type="none"/><a:tailEnd type="arrow" w="med" len="med"/></a:ln> </p:spPr></p:cxnSp>""" sp_tree.append(etree.fromstring(xml)) # ══════════════════════════════════════════════════ # New slide: Investigation of Cushing's Syndrome # ══════════════════════════════════════════════════ s = prs.slides.add_slide(blank) set_bg(s, RGBColor(0xF7,0xF9,0xFF)) # Header hdr = s.shapes.add_shape(1, Inches(0), Inches(0), Inches(13.333), Inches(1.05)) hdr.fill.solid(); hdr.fill.fore_color.rgb = C_TITLE_BG; hdr.line.fill.background() add_label(s, 0.3, 0.08, 12.7, 0.85, "Investigation of Cushing's Syndrome — Step-by-Step Approach", size=24, bold=True, align=PP_ALIGN.LEFT, rgb=C_WHITE) # ── STEP 1: Exclude Iatrogenic ─────────────────── add_box(s, 0.25, 1.1, 12.8, 0.55, C_BOX_GREY, "STEP 1 — First exclude IATROGENIC Cushing's: rule out exogenous corticosteroid use (oral, inhaled, topical, parenteral)", fsize=11, bold=False) # ── STEP 2: Screening header ───────────────────── add_box(s, 0.25, 1.75, 12.8, 0.42, C_TITLE_BG, "STEP 2 — SCREENING TESTS (Confirm hypercortisolism — Endocrine Society 2008: ≥2 tests abnormal required)", fsize=11, bold=True, border=C_TITLE_BG, align=PP_ALIGN.LEFT) # force white text shape = s.shapes[-1] shape.text_frame.paragraphs[0].runs[0].font.color.rgb = C_WHITE scr = [ ("Late-night Salivary Cortisol ×2", "Loss of diurnal rhythm; cortisol normally at nadir at midnight;\nRaised = abnormal; non-invasive, validated for Cushing's screening", C_BOX_BLUE), ("24-hr Urinary Free Cortisol (UFC) ×2", ">3× upper limit of normal = significant hypercortisolism;\nPreferred in pregnancy and severe renal failure", C_BOX_BLUE), ("Overnight 1-mg DST", "Morning cortisol >50 nmol/L (>1.8 µg/dL) = non-suppressed = abnormal", C_BOX_BLUE), ("2-mg 48-hr DST", "Preferred when pseudo-Cushing states present:\ndepression, obesity, alcoholism, diabetes mellitus", C_BOX_BLUE), ] for i, (lbl, body, fill) in enumerate(scr): rx = 0.25 + i * 3.28 add_box(s, rx, 2.22, 2.3, 0.42, C_BOX_ORANGE, lbl, fsize=10, bold=True) add_box(s, rx, 2.68, 2.3, 0.72, fill, body, fsize=9) # ── STEP 3: ACTH ──────────────────────────────── add_box(s, 0.25, 3.48, 12.8, 0.42, C_TITLE_BG, "STEP 3 — PLASMA ACTH (Determine ACTH-dependency)", fsize=11, bold=True, border=C_TITLE_BG) s.shapes[-1].text_frame.paragraphs[0].runs[0].font.color.rgb = C_WHITE add_box(s, 0.25, 3.95, 6.2, 0.58, C_BOX_YELLOW, "ACTH ELEVATED (>20 pg/mL) → ACTH-Dependent (~80%)\nCushing's disease (pituitary) or Ectopic ACTH", fsize=10, bold=True) add_box(s, 6.65, 3.95, 6.4, 0.58, C_BOX_GREEN, "ACTH SUPPRESSED (<5 pg/mL) → ACTH-Independent (~20%)\nAdrenal adenoma / Carcinoma / Bilateral hyperplasia", fsize=10, bold=True) # ── STEP 4A: ACTH-dependent ────────────────────── add_box(s, 0.25, 4.62, 6.2, 0.38, C_BOX_YELLOW, "STEP 4A — If ACTH-Dependent", fsize=10, bold=True) dep = [ "Pituitary MRI — microadenoma (<10 mm); low sensitivity alone", "High-dose DST (8 mg) — suppression >50% = Cushing's disease", "CRH stimulation test — exaggerated rise = pituitary source", "Bilateral Inferior Petrosal Sinus Sampling (BIPSS) — gold standard\n to distinguish pituitary vs ectopic ACTH", "If ectopic suspected: CT thorax/abdomen/pelvis;\n ⁶⁸Ga-SSTR PET-CT (75–80% sensitive for ectopic source)", ] for i, pt in enumerate(dep): ry = 5.05 + i * 0.43 add_box(s, 0.25, ry, 6.2, 0.40, C_BOX_YELLOW, "• " + pt, fsize=9) # ── STEP 4B: ACTH-independent ──────────────────── add_box(s, 6.65, 4.62, 6.4, 0.38, C_BOX_GREEN, "STEP 4B — If ACTH-Independent", fsize=10, bold=True) indep = [ "CT or MRI of adrenal glands", "Unilateral adenoma — benign: hypodense, <10 HU on non-contrast CT", "Bilateral nodular hyperplasia — consider AIMAH or Carney complex", "Adrenocortical carcinoma — large, irregular, heterogeneous", "First exclude surreptitious glucocorticoid administration", ] for i, pt in enumerate(indep): ry = 5.05 + i * 0.43 add_box(s, 6.65, ry, 6.4, 0.40, C_BOX_GREEN, "• " + pt, fsize=9) # Footer add_label(s, 0.2, 7.08, 12.9, 0.35, "References: Bailey & Love's Surgery 28e p.8032–8068 | Berek & Novak's Gynaecology p.88 | Quick Compendium Clinical Pathology 5e p.3470–3481 | Endocrine Society Clinical Practice Guidelines 2008", size=7.5, rgb=RGBColor(0x88,0x88,0x88)) # Save buf = BytesIO() prs.save(buf) with open("Cortisol_Metabolism.pptx","wb") as f: f.write(buf.getvalue()) print("Done — slide added successfully.") EOF

Done! The new slide has been added to your presentation.

Cortisol Metabolism

Presentation · PPTX


Here is a clean summary of all the bullet points on the new slide:
STEP 1 — Exclude Iatrogenic Cushing's
  • Rule out exogenous corticosteroid use (oral, inhaled, topical, parenteral)
STEP 2 — Screening Tests (Endocrine Society 2008: ≥2 tests must be abnormal)
  • Late-night salivary cortisol ×2 - loss of diurnal rhythm
  • 24-hr urinary free cortisol (UFC) ×2 - >3× upper limit = significant
  • Overnight 1-mg DST - cortisol >50 nmol/L = non-suppressed
  • 2-mg 48-hr DST - preferred in pseudo-Cushing states (depression, obesity, alcoholism, diabetes)
STEP 3 — Plasma ACTH
  • Elevated (>20 pg/mL) → ACTH-dependent (~80%)
  • Suppressed (<5 pg/mL) → ACTH-independent (~20%)
STEP 4A — If ACTH-Dependent
  • Pituitary MRI (microadenoma, <10 mm)
  • High-dose DST (8 mg) - suppression >50% = Cushing's disease
  • CRH stimulation test - exaggerated rise = pituitary source
  • Bilateral inferior petrosal sinus sampling (BIPSS) - gold standard to distinguish pituitary vs ectopic
  • If ectopic: CT thorax/abdomen/pelvis; ⁶⁸Ga-SSTR PET-CT (75-80% sensitive)
STEP 4B — If ACTH-Independent
  • CT/MRI adrenals - adenoma, bilateral hyperplasia, or carcinoma
  • Benign adenoma: hypodense, <10 HU on non-contrast CT

Exogenous cusgings syndrome and role of synaten test and

Exogenous Cushing's is caused by prolonged external glucocorticoid use. The Synacthen (ACTH stimulation) test is used to assess adrenal reserve in this context. Let me pull the full detail from the textbooks.
Searching sources...
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Excellent - I now have comprehensive information from Harrison's, Campbell Walsh, Goldman-Cecil, Mulholland, and Miller's Anaesthesia. Here is the full answer:

Exogenous (Iatrogenic) Cushing's Syndrome & the Synacthen Test


What is Exogenous Cushing's Syndrome?

Exogenous (iatrogenic) Cushing's syndrome is caused by prolonged external glucocorticoid administration - it is by far the most common cause of Cushing's syndrome overall, affecting approximately 1% of the Western population on chronic steroid therapy.
  • Harrison's Principles of Internal Medicine 22e, p. 964
  • Campbell Walsh Wein Urology, p. 1832

Causes / Sources of Exogenous Glucocorticoids

  • Oral: prednisolone, dexamethasone, hydrocortisone (most common and potent route)
  • Inhaled: fluticasone ≥750 mcg/day or beclomethasone ≥1500 mcg/day for >3 weeks
  • Topical: high-potency creams >2 g/day for >2 weeks
  • Intra-articular / epidural / spinal: 3 or more injections within 3 months
  • Ophthalmic / ototopical: can also cause HPA suppression
  • Surreptitious use: herbal remedies, nasal sprays, performance-enhancing drugs - patient may be unaware

Key Pathophysiology

When exogenous glucocorticoids are taken:
Exogenous glucocorticoid
        ↓
Negative feedback on hypothalamus + pituitary
        ↓
↓ CRH  →  ↓ ACTH  →  Adrenal cortex loses ACTH stimulation
        ↓
Adrenocortical cells undergo apoptosis + atrophy
(all cells except aldosterone-producing zona glomerulosa)
        ↓
Secondary adrenal insufficiency
  • Without ACTH, glucocorticoid-producing adrenal cells arrest hormone production and undergo apoptosis
  • Goldman-Cecil Medicine, p. 2728; Campbell Walsh Urology, p. 1819

Clinical Features of Exogenous Cushing's

Same as endogenous Cushing's PLUS specific differences:
FeatureNotes
Central obesity, moon face, buffalo humpClassic Cushingoid appearance
Skin fragility, easy bruising, striaeVery common with steroids
Proximal myopathyCharacteristic
Osteoporosis / osteonecrosisMajor complication, often femoral head
Hypertension, hyperglycaemiaCommon
Poor wound healingImpaired immunity
Posterior subcapsular cataracts
Hyperlipidaemia
Growth retardation (children)
ACTH very LOW / suppressedKey distinguishing feature from endogenous
Adrenal glands atrophied / smallOn imaging - opposite of Cushing's disease
No hyperpigmentation(No excess ACTH to stimulate melanocytes)
Risk of adrenal crisis on withdrawalCritical danger - do NOT stop steroids abruptly

The Synacthen (Short ACTH Stimulation) Test

Synacthen = synthetic ACTH (cosyntropin/tetracosactide). The Short Synacthen Test (SST) is the standard test to:
  1. Confirm adrenal insufficiency
  2. Assess the degree of HPA axis suppression after prolonged steroid use
  3. Guide safe steroid tapering

Protocol:

StepDetail
BaselineMeasure serum cortisol at time 0
Injection250 mcg Synacthen IV (or IM) bolus
Re-measureSerum cortisol at 30 minutes and 60 minutes

Interpretation:

ResultMeaning
Peak cortisol >500 nmol/L (>18 µg/dL)NORMAL - adrenal reserve intact, HPA axis not significantly suppressed
Peak cortisol <500 nmol/L (<18 µg/dL)ABNORMAL - adrenal insufficiency confirmed (92% sensitive)
Peak cortisol >20 µg/dLNormal per some centres (Mulholland Surgery criteria)
  • Symptom to Diagnosis 4th ed, p. 7499; Mulholland & Greenfield's Surgery 7e, p. 2743

Why the SST Can Be FALSELY NORMAL in Exogenous Cushing's

This is a critical clinical point:
  • Chronic HPA suppression (>1 month) → adrenal atrophy → adrenal cannot respond to Synacthen → SST positive (abnormal) - correctly detected
  • Acute/recent HPA suppression (e.g., just stopped steroids, recent pituitary surgery) → adrenal gland not yet atrophied → Synacthen still stimulates cortisol → falsely normal SST
  • In acute cases, the Insulin Tolerance Test (ITT) or metyrapone test is needed to challenge the whole hypothalamic-pituitary axis

When to Suspect HPA Suppression (Do the Synacthen Test)

Steroid dose/durationHPA suppression riskAction
<7.5 mg prednisolone/day, any durationUnlikelyNo test needed; take usual morning dose
Any dose, <3 weeksUnlikelyNo test needed
7.5–20 mg/day, >3 weeksUncertain - likelyConsider SST
>20 mg/day, >3 weeksLikelyAssume suppressed; perioperative steroid cover required
Inhaled fluticasone ≥750 mcg/day, >3 weeksRiskConsider SST preoperatively
  • Miller's Anaesthesia 10e, p. 84-86; Barash's Clinical Anaesthesia 9e, p. 2541

Management of Exogenous Cushing's / Steroid Withdrawal

  • Never stop abruptly - risk of adrenal crisis (hypotension, vomiting, shock, death)
  • Gradual taper to allow HPA axis recovery - may take weeks to months
  • Adrenal insufficiency risk after withdrawal estimated at ~30% across all routes of administration
  • Use SST to confirm HPA recovery before stopping completely
  • During illness or surgery - give stress doses of hydrocortisone:
  • Minor surgery: 25 mg hydrocortisone on day of procedure
  • Moderate surgery: 50-75 mg hydrocortisone, taper over 1-2 days
  • Major surgery: 100-150 mg hydrocortisone/day, tapered over 2-3 days
  • Goldman-Cecil Medicine, p. 2728; Miller's Anaesthesia 10e, p. 86-93

Sources: Harrison's 22e p.964-966 | Campbell Walsh Wein Urology p.1819-1833 | Goldman-Cecil Medicine p.2724-2730 | Mulholland & Greenfield's Surgery 7e p.2739-2743 | Miller's Anaesthesia 10e p.84-93 | Barash's Clinical Anaesthesia 9e p.2541 | Symptom to Diagnosis 4e p.7497-7511

how to known biochemically exogenouss strid intake

The key biochemical hallmark of exogenous steroid intake is suppressed ACTH + suppressed endogenous cortisol, opposite to endogenous Cushing's. Let me pull the full textbook detail.
Searching sources...
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
I now have all the information needed. Here is the complete answer:

How to Identify Exogenous Steroid Intake Biochemically

The biochemical pattern of exogenous Cushing's is the mirror image of endogenous Cushing's. The key principle: exogenous steroids suppress the HPA axis, so endogenous cortisol falls while ACTH is undetectable.

The Core Biochemical Fingerprint

TestExogenous Cushing'sEndogenous Cushing's (e.g. Cushing's disease)
Plasma ACTHVery LOW / undetectable (<5 pg/mL)Elevated (pituitary) or very high (ectopic)
Serum cortisol (morning)LOW / suppressedElevated
24-hr Urinary Free Cortisol (UFC)LOW (endogenous cortisol suppressed)Elevated (>3× ULN)
Late-night salivary cortisolLOWElevated (diurnal rhythm lost)
Dexamethasone suppression test (DST)Paradoxically SUPPRESSED alreadyFails to suppress
Adrenal size on imagingSmall / atrophied bilaterallyEnlarged / hyperplastic
  • Tietz Textbook of Laboratory Medicine 7e, pp. 2221-2226; Campbell Walsh Urology, p. 1963

Detailed Biochemical Tests & Their Interpretation

1. Plasma ACTH (Most Discriminating Single Test)

  • Exogenous glucocorticoids exert negative feedback on the hypothalamus (↓ CRH) and pituitary (↓ ACTH)
  • Result: ACTH suppressed to <5 pg/mL or undetectable
  • This is the single most useful test to distinguish exogenous from endogenous causes
  • In Cushing's disease ACTH is high; in ectopic ACTH syndrome it can be >300 pg/mL
  • In exogenous Cushing's it is paradoxically opposite - near zero

2. Serum Cortisol

  • Morning serum cortisol is LOW - endogenous production suppressed
  • Normal morning range: 5-25 µg/dL (140-690 nmol/L); in exogenous Cushing's, may be <3 µg/dL
  • BUT: Important assay caveat - some synthetic steroids (prednisolone, hydrocortisone) cross-react with cortisol immunoassays, giving falsely ELEVATED readings
  • Prednisolone shows variable cross-reactivity with cortisol antibodies - can falsely inflate measured cortisol
  • Dexamethasone does NOT cross-react with cortisol immunoassays - this is why dexamethasone is used in suppression tests (endogenous cortisol can still be measured accurately)
  • HPLC-MS/MS (liquid chromatography-mass spectrometry) is the gold standard - can separately measure cortisol AND identify specific exogenous steroids simultaneously
  • Tietz Textbook of Laboratory Medicine 7e, pp. 2444-2446; Henry's Clinical Diagnosis by Laboratory Methods, p. 1761

3. Urinary Free Cortisol (24-hr UFC)

  • Exogenous Cushing's → endogenous cortisol suppressed → UFC is LOW or undetectable
  • Endogenous Cushing's → UFC is elevated (>3× upper limit of normal)
  • A low UFC with Cushingoid features = strongly suggests exogenous source

4. Direct Detection of Exogenous Steroids in Urine or Serum

This is the definitive proof:
SteroidDetected by
Prednisolone / prednisoneUrinary steroid profile (GC-MS / HPLC-MS) - prednisolone and its metabolites detected in urine
DexamethasoneSerum/urine dexamethasone levels by HPLC-MS; does NOT cross-react with cortisol assays
Budesonide, fluticasoneSpecialist mass spectrometry panels
MethylprednisoloneUrinary metabolites on steroid profile
  • A 24-hr urine steroid profile by GC-MS will show:
  • Absent or very low tetrahydrocortisol (THF), allo-THF, tetrahydrocortisone (THE) - endogenous metabolites suppressed
  • Presence of exogenous steroid metabolites (prednisolone metabolites, etc.)

5. Dexamethasone Suppression Test (DST) - Paradoxical Response

  • In endogenous Cushing's: cortisol fails to suppress after 1mg dexamethasone (>50 nmol/L = abnormal)
  • In exogenous Cushing's: if the patient is taking dexamethasone themselves, cortisol will appear suppressed - but this is misleading
  • If taking other steroids (prednisolone): the DST may give confusing results because prednisolone cross-reacts with the cortisol assay
  • Key: dexamethasone does not cross-react with cortisol immunoassay, making it the ideal suppressing agent for diagnostic testing
  • Tietz Textbook, p. 2444

6. Synacthen (Short ACTH Stimulation) Test in Exogenous Cushing's

This test reveals the functional consequence of exogenous steroid use:
  • After prolonged exogenous steroid use → adrenal cortex atrophies from lack of ACTH stimulation
  • Give 250 µg Synacthen IV → measure cortisol at 30 and 60 min
  • Result in exogenous Cushing's (chronic):
  • Blunted/absent cortisol rise (peak <500 nmol/L = <18 µg/dL)
  • Confirms secondary adrenal insufficiency due to HPA suppression
  • Interpretation caveat: if steroid use is recent/short-term (<1 month), adrenal atrophy has not yet occurred and the SST may be falsely normal - the ITT (insulin tolerance test) is then needed

Summary Algorithm: "Is This Exogenous Steroid Use?"

Patient has Cushingoid features
            ↓
STEP 1: History → any steroid use? (including hidden sources)
            ↓
STEP 2: Plasma ACTH
   Low/undetectable → ACTH-independent
            ↓
STEP 3: Serum cortisol (morning)
   LOW → suggests exogenous (not an autonomous adrenal tumour)
            ↓
STEP 4: 24-hr UFC
   LOW → further supports exogenous
            ↓
STEP 5: HPLC-MS/MS urine steroid profile
   Absent endogenous metabolites (THF/THE) + exogenous steroid metabolites DETECTED
            ↓
STEP 6: Adrenal imaging (CT/MRI)
   Both adrenals SMALL/ATROPHIED → confirms no autonomous adrenal tumour
            ↓
STEP 7: Short Synacthen Test
   Flat response → HPA suppression from chronic exogenous steroid use CONFIRMED

Key Distinguishing Points at a Glance

FeatureExogenousEndogenous (Cushing's disease)Adrenal adenoma
ACTH↓↓ undetectable↑ (normal-high)
Morning cortisol
UFC↑↑
Adrenal size↓ (atrophied)↑ (hyperplastic)Unilateral mass
DST responseSuppressed (cortisol already low)Fails to suppressFails to suppress
SynacthenFlat / bluntedNormal or exaggeratedFlat (contralateral atrophy)
Exogenous steroid in urinePRESENTAbsentAbsent

Sources: Tietz Textbook of Laboratory Medicine 7e pp. 2203-2446 | Henry's Clinical Diagnosis by Laboratory Methods pp. 1761-1763 | Campbell Walsh Wein Urology pp. 1962-1964 | Goldman-Cecil Medicine pp. 2728-2730 | Mulholland & Greenfield's Surgery 7e p. 2354

from endocrine soirty guidelines i want 8am cortsiol velues

Good question - the Endocrine Society guidelines give specific 8 AM cortisol cut-offs for adrenal insufficiency and Cushing's. Let me pull the exact values.
Searching sources...
Finding Sources
Searching PubMed

"Endocrine Society" guideline cortisol 8am morning adrenal insufficiency Cushing

Finding Sources
Searching PubMed

"adrenal insufficiency" diagnosis "morning cortisol" cutoff guideline

Searching the Web

Endocrine Society guidelines 8am cortisol values cutoff adrenal insufficiency Cushing syndrome 2016

Reading File
Reading File
Reading Web Page

https://pmc.ncbi.nlm.nih.gov/articles/PMC2605410

I now have all the exact Endocrine Society values from multiple guidelines. Here is the complete, clean answer:

Endocrine Society Guidelines — 8 AM Cortisol Values

There are two separate Endocrine Society guidelines that give 8 AM cortisol cut-offs, used for different clinical questions:

GUIDELINE 1: Diagnosis of Adrenal Insufficiency (2016)

(Primary + Central/Secondary Adrenal Insufficiency)
The 8 AM (morning) serum cortisol is the first-line test.
8 AM Cortisol ValueInterpretationAction
≥ 18 µg/dL (≥ 500 nmol/L)Adrenal insufficiency EXCLUDED - sufficient adrenal functionNo further testing needed
< 3 µg/dL (< 83 nmol/L)Adrenal insufficiency CONFIRMED - strongly diagnosticCheck 8 AM ACTH to distinguish primary vs secondary
3–15 µg/dL (83–415 nmol/L)Indeterminate / Grey zoneProceed to Short Synacthen Test (SST)
> 15 µg/dL (> 415 nmol/L)AI unlikelyCan likely exclude AI
"Morning serum cortisol ≤3 mcg/dL is strongly suggestive of adrenal insufficiency; morning serum cortisol ≥18 mcg/dL assures sufficient adrenal function."
  • Mulholland & Greenfield's Surgery 7e, Endocrine Society 2016 Central AI Guidelines
Additional evidence-based thresholds (Symptom to Diagnosis 4e):
  • Morning cortisol ≥ 16.3 µg/dL → rules OUT adrenal insufficiency (99.2% sensitive)
  • Morning cortisol ≤ 3.6 µg/dL → establishes adrenal insufficiency (98.4% specific)
  • Morning cortisol 3.6–16.3 µg/dL → non-diagnostic → do Synacthen test

GUIDELINE 2: Diagnosis of Cushing's Syndrome (2008)

(Screening for Hypercortisolism)
Here the 8 AM cortisol is used after the overnight 1-mg Dexamethasone Suppression Test (DST):
8 AM Cortisol (after 1 mg DEX at 11 PM)Interpretation
> 1.8 µg/dL (> 50 nmol/L)ABNORMAL - cortisol not suppressed = possible Cushing's syndrome (sensitivity >95%)
≤ 1.8 µg/dL (≤ 50 nmol/L)NORMAL - cortisol suppressed = Cushing's unlikely
Old cut-off (not recommended): > 5 µg/dL (140 nmol/L)Less sensitive - the Society recommends 1.8 µg/dL instead
The guideline recommends the 1.8 µg/dL (50 nmol/L) cut-off rather than the older 5 µg/dL cut-off - achieves sensitivity >95% (with lower specificity of ~80%)
  • Endocrine Society Cushing's Guidelines 2008, Nieman et al. JCEM 93(5):1526–1540

GUIDELINE 3: Post-surgical Cushing's Remission

(Treatment of Cushing's Syndrome 2015)
After successful surgery for Cushing's disease:
8 AM CortisolMeaning
< 1.8 µg/dL (< 50 nmol/L)Remission confirmed - indicates HPA suppression
UndetectableAfter bilateral adrenalectomy - as expected

Quick Summary Table — All Endocrine Society 8 AM Cortisol Cut-offs

Clinical ContextCut-offMeaning
Cushing's screening (post 1mg DST)> 1.8 µg/dL (50 nmol/L)Abnormal = possible Cushing's
Adrenal insufficiency confirmed< 3 µg/dL (83 nmol/L)AI diagnostic - check ACTH
Grey zone - do Synacthen3–15 µg/dL (83–415 nmol/L)Indeterminate - SST required
Adrenal insufficiency excluded≥ 18 µg/dL (500 nmol/L)Sufficient adrenal reserve
Post-Cushing's remission< 1.8 µg/dL (50 nmol/L)Confirms surgical remission

Important note: Always collect the 8 AM sample between 08:00 and 09:00 hours - cortisol is at its physiological peak at this time. Testing must be done at least 18-24 hours after last hydrocortisone dose (or longer for synthetic glucocorticoids like dexamethasone/prednisolone).
Sources: Endocrine Society Central AI Guidelines 2016 (JCEM) | Endocrine Society Cushing's Guidelines 2008 (Nieman et al. JCEM 93:1526) | Endocrine Society Treatment of Cushing's 2015 (PMC4525003) | Symptom to Diagnosis 4e p.7456 | Mulholland & Greenfield's Surgery 7e p.3052

howto differeenciate between exogenus and endogenus

The key is that exogenous steroids suppress the HPA axis while endogenous Cushing's activates it. Let me pull the full textbook detail on differentiation.
Searching sources...
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
I now have all the information needed. Here is the complete, structured comparison:

Differentiating Exogenous vs Endogenous Cushing's Syndrome


STEP 1 — Clinical History (Most Important First Step)

FeatureExogenousEndogenous
Steroid use historyYES - oral, inhaled, topical, injectedNo steroid use
OnsetCorresponds with steroid therapy startGradual, insidious
Hidden sourcesHerbal remedies, nasal sprays, eye drops, surreptitious useNone
Always take a thorough drug history first - including over-the-counter and herbal products. This is the single most important step.

STEP 2 — Clinical Signs Comparison

Clinical FeatureExogenousEndogenous
Moon face, buffalo hump, central obesity✓ Present✓ Present
Purple striae, easy bruising, thin skin✓ Present✓ Present
Proximal myopathy✓ Present✓ Present
Hypertension, hyperglycaemia✓ Present✓ Present
HyperpigmentationABSENT (ACTH low - no melanocyte stimulation)PRESENT in ectopic ACTH (very high ACTH); mild in Cushing's disease
Adrenal androgen features (hirsutism, acne, virilisation)ABSENT (adrenal androgen production suppressed)Present - especially in adrenal carcinoma
Growth retardation (children)Can occurCan occur
Severe rapid-onset hypokalaemiaRareCharacteristic of ectopic ACTH syndrome (~70%)
Osteoporosis
  • Harrison's 22e, p. 2518-2520

STEP 3 — Biochemical Differentiation (The Core)

This is the definitive step. The entire HPA axis behaves in opposite directions:
Biochemical TestExogenousEndogenous - Cushing's Disease (pituitary)Endogenous - Ectopic ACTHEndogenous - Adrenal Adenoma
Plasma ACTH↓↓ Undetectable / <5 pg/mL↑ Normal-high (20-200 pg/mL)↑↑↑ Very high (>300 pg/mL)↓ Suppressed
Serum cortisol (8 AM)↓ LOW (endogenous suppressed)↑ Elevated↑↑ Elevated↑ Elevated
24-hr Urinary Free Cortisol (UFC)LOW↑↑ High (>3× ULN)↑↑↑ Very high↑ High
Late-night salivary cortisol↓ Low↑ High (diurnal rhythm lost)↑↑ High↑ High
1-mg overnight DSTCortisol already suppressedFails to suppress (>1.8 µg/dL)Fails to suppressFails to suppress
Adrenal size (CT/MRI)Bilateral atrophy - SMALLBilateral hyperplasiaBilateral hyperplasiaUnilateral adenoma
Synacthen testFLAT (atrophied adrenals)Normal or exaggeratedNormal or exaggeratedFlat (contralateral side atrophied)
Direct steroid in urine/serumDETECTED (prednisolone, dexamethasone metabolites)Not detectedNot detectedNot detected
Urine steroid profile (GC-MS)Absent THF/THE (endogenous metabolites suppressed); exogenous steroid metabolites present↑ THF, ↑ THE↑ THF, ↑ THE↑ THF, low THE ratio
  • Harrison's 22e, p. 2525; Campbell Walsh Urology, p. 1963; Tietz Textbook of Laboratory Medicine 7e, p. 1813

STEP 4 — Key Distinguishing Tests at a Glance

A. Plasma ACTH — The Most Discriminating Single Test

ACTH undetectable (<5 pg/mL)
         ↓
ACTH-independent Cushing's
         ↓
Adrenal CT/MRI:
   • Normal / small adrenals → EXOGENOUS steroid use
   • Unilateral adenoma → Adrenal adenoma
   • Bilateral hyperplasia → Bilateral nodular hyperplasia

B. 24-hr UFC

  • LOW UFC + Cushingoid features = EXOGENOUS (endogenous production suppressed)
  • HIGH UFC = ENDOGENOUS (autonomous cortisol production)

C. Direct Steroid Identification (Mass Spectrometry - Definitive)

  • HPLC-MS/MS serum or urine can directly detect and quantify:
  • Prednisolone and its metabolites (prednisolone/prednisone)
  • Dexamethasone (note: does NOT cross-react with cortisol immunoassays)
  • Methylprednisolone, budesonide, fluticasone metabolites
  • Endogenous metabolites (THF, allo-THF, THE) are absent or very low in exogenous Cushing's
  • This is the gold standard for confirming exogenous steroid intake

D. Hyperpigmentation

  • Present → suggests high ACTH (endogenous - ectopic ACTH most pronounced)
  • Absent → supports exogenous OR adrenal adenoma (both suppress ACTH)

Summary Comparison Table

FeatureExogenousEndogenous (Cushing's Disease)Ectopic ACTH
ACTH↓ Undetectable↑ Moderately raised↑↑↑ Very high
Cortisol (8 AM)↓ Low↑ High↑↑ Very high
UFC↓ Low↑↑ High↑↑↑ Very high
Hyperpigmentation✗ No± Mild✓✓ Pronounced
HypokalaemiaRareOccasional (<10%)Common (~70%)
Adrenal sizeBilateral atrophy ↓Bilateral hyperplasia ↑Bilateral hyperplasia ↑
Synacthen testFlat (atrophied)Normal/exaggeratedNormal/exaggerated
Drug in urine✓ DETECTED✗ Absent✗ Absent
DST (1 mg)Already suppressedFails to suppressFails to suppress

Sources: Harrison's Principles of Internal Medicine 22e pp. 2516-2525 | Campbell Walsh Wein Urology pp. 1961-1964 | Tietz Textbook of Laboratory Medicine 7e pp. 1813, 2203-2226 | Mulholland & Greenfield's Surgery 7e p. 3052 | Symptom to Diagnosis 4e pp. 7456-7458

Would you like details on the Synacthen (ACTH stimulation) test protocol and interpretation?1 edition waht is it page number

Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
I now have all the exact page numbers and content. Here is the answer:

Synacthen (Short ACTH Stimulation) Test — Protocol & Interpretation

Your question is about which edition and page number. Here are the exact textbook sources that cover this test in detail:

Source Books & Page Numbers

TextbookEditionPage / Section
Bailey and Love's Short Practice of Surgery28th Editionp. 915 & p. 8380 (Synacthen test for adrenal insufficiency diagnosis)
Goldman-Cecil Medicine26th Edition (International)p. 4064-4067 (Cosyntropin as gold standard)
Mulholland and Greenfield's Surgery7th Editionp. 2739-2743 (Rapid ACTH stimulation test protocol)
The Washington Manual of Medical TherapeuticsCurrent Editionp. 5803-5805 (Cosyntropin 250 µg protocol)
Henry's Clinical Diagnosis & Management by Laboratory MethodsCurrent Editionp. 1905-1907 (Serum cortisol normal response)
Tietz Textbook of Laboratory Medicine7th Editionp. 342-344 (Cosyntropin/Synacthen stimulation test)
Symptom to Diagnosis: An Evidence-Based Guide4th Editionp. 7487-7499 (Full diagnostic algorithm with CST)

Protocol (from Goldman-Cecil Medicine p. 4064-4065 & Tietz p. 342-344)

StepDetail
DrugSynacthen (tetracosactide) = Cosyntropin 250 µg IV or IM
TimingCan be done at any time of day (for standard dose); morning preferred
BaselineDraw blood for cortisol + ACTH at time 0 before injection
InjectionGive 250 µg Synacthen IV bolus (or IM)
SamplingSerum cortisol at 30 minutes and 60 minutes after injection

Interpretation of Results

Peak Cortisol ResponseInterpretation
> 18 µg/dL (> 500 nmol/L) at 30 or 60 minNORMAL - adrenal function adequate (Endocrine Society / most centres)
> 20 µg/dL at 30 or 60 minNORMAL (older Mulholland / Greenfield criteria, p. 2743)
< 18 µg/dL at 30 or 60 minABNORMAL - adrenal insufficiency confirmed (92% sensitive)
<14 µg/dL (if LC-MS/MS used)ABNORMAL - when measured by tandem mass spectrometry (more specific)
Important distinction from Goldman-Cecil p. 4065: When measured by standard immunoassay that cross-reacts with cortisol precursors, the cut-off is >18 µg/dL. When measured by tandem mass spectrometry or monoclonal antibody assay (more specific), the upper limit of normal drops to ~14 µg/dL.

What the ACTH Level Tells You (Bailey & Love p. 8380-8382)

After the Synacthen test, measure basal ACTH:
ACTHCortisolDiagnosis
Low / undetectableLow, fails to riseSecondary / Tertiary adrenal insufficiency (pituitary or hypothalamic cause - e.g. exogenous steroid suppression)
High (> 200 pg/mL)Low, fails to risePrimary adrenal insufficiency (Addison's - adrenal gland destroyed)
LowLow, fails to riseExogenous steroid use - adrenal atrophied from ACTH deprivation

Low-Dose Synacthen Test (1 µg)

  • A 1 µg IV dose has been proposed as more sensitive for detecting early or mild HPA suppression (e.g. partial pituitary insufficiency)
  • Must be done in the morning to be valid
  • Technically harder to formulate accurately - risk of falsely normal result due to dose errors
  • Not universally adopted; remains controversial
  • Goldman-Cecil Medicine, p. 4067; Tietz Textbook, p. 344

Limitations (Tietz p. 344 / Symptom to Diagnosis p. 7507)

  • False normal in acute secondary AI: if pituitary has just been damaged (e.g. recent pituitary surgery or infarction within <4 weeks), adrenal has not yet atrophied - will still respond to Synacthen even though HPA axis is disrupted
  • In such cases → Insulin Tolerance Test (ITT) or metyrapone test is needed to challenge the entire HPA axis
  • ITT is contraindicated in: age >70, cardiac disease, seizure disorder, severe debility
  • Glucagon stimulation test = alternative to ITT when hypoglycaemia is contraindicated

Primary references with page numbers:
  • Bailey & Love's Short Practice of Surgery 28e — pp. 8380-8382
  • Goldman-Cecil Medicine 26e — pp. 4064-4067
  • Mulholland & Greenfield's Surgery 7e — pp. 2739-2743
  • Tietz Textbook of Laboratory Medicine 7e — pp. 342-344
  • Symptom to Diagnosis 4e — pp. 7487-7511
  • Washington Manual of Medical Therapeutics — pp. 5803-5805
This is a shared conversation. Sign in to Orris to start your own chat.